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This manuscript offers an approach to the treatment of pulmonary sarcoidosis based on current
available information. The treatment of pulmonary sarcoidosis is not mandatory as the disease
may be self-limiting and therapy is often associated with significant drug side effects. The
decision to treat rests predominantly on the presence of significant symptoms or functional
limitation. Corticosteroids are the drug of choice. Alternative agents to corticosteroids may
be useful primarily as corticosteroid sparing agents.
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1352 M.A. JudsonIntroduction Granulomatous InflammationFibrosis with permanent 
lung damage Resolution
With or without 
therapy
Relapse
? Host factors
Figure 1 The natural course of pulmonary sarcoidosis.
Granulomatous inflammation may resolve with or without
therapy. Relapse occurs when granulomatous inflammation
redevelops. Fibrosis is suspected to be related to granuloma-
tous inflammation, probably influenced by host factors.The decision to treat a medical condition depends upon
several factors including the natural course of the disease,
the expected response to treatment, and the potential
toxicity of therapy.1 Pulmonary sarcoidosis poses unique
treatment dilemmas because the natural course of the
disease is problematic to predict, the methods to assess
outcome are not standardized, and the risk of toxicity from
anti-sarcoidosis therapies is significant.
This manuscript will outline an approach to the treat-
ment of pulmonary sarcoidosis based on the limited clinical
data currently available. The therapeutic strategies offered
here should not be viewed as definitive but rather as
a “best guess” given our present state of knowledge. This
manuscript will cover the following topics: below:
1. The natural history of pulmonary sarcoidosis and the
effect of therapy
2. The decision to treat
2a. Newly diagnosed disease
2b. Therapy for established disease
3. Specific pharmacotherapy
3a. Recommended corticosteroid treatment course
3b. Therapy for relapse
3c. Therapy for pulmonary fibrosis from sarcoidosis
4. SummaryThe natural history of pulmonary sarcoidosis
and the effect of therapy
The clinical course of pulmonary sarcoidosis is depicted in
Fig. 1. The disease causes granulomatous inflammation in
the lung that may clear with or without therapy. All
effective anti-sarcoidosis therapies are able to terminate
the granulomatous inflammation of sarcoidosis. When
effective therapy is withdrawn, the granulomatous inflam-
mation may redevelop, and the disease is then said to have
“relapsed.” It is thought that the granulomatous inflam-
mation of pulmonary sarcoidosis per se does not result in
permanent lung damage. Rather, the lung is irrevocably
damaged when fibrosis develops. It is assumed, although
not proven, that fibrosis is a by-product of the granuloma-
tous inflammation of sarcoidosis. It is likely that several
host factors are important in the development of lung
scarring. In addition, many patients with parenchymal
lesions on lung imaging (consistent with granulomatous
inflammation) detected for several years eventually
normalize their pulmonary function and lung imaging sug-
gesting that fibrosis never developed.2
The decision to treat
Newly diagnosed disease
If the schema just described is accurate, it has significant
implications concerning the treatment of newly diagnosed
pulmonary sarcoidosis. First, because the granulomatous
burden within the lung may resolve spontaneously, it onlyrequires treatment if it causes significant pulmonary
symptoms or functional limitation. Because the standard
therapy for pulmonary sarcoidosis is corticosteroids which
are associated with significant side effects, patients with
mild or no pulmonary symptoms are usually best served by
being monitored without therapy. Inhaled corticosteroids
could be considered for patients with sarcoidosis related
cough.3 Second, a pulmonary sarcoidosis patient with
evidence of granulomatous inflammation and/or pulmonary
dysfunction that is associated with significant pulmonary
symptoms/functional limitation should be considered for
treatment. If the pulmonary symptoms/functional limita-
tion does not greatly affect the patient’s quality of life, the
patient may be observed without therapy. If a patient is
observed without therapy, treatment should be initiated if
there is significant deterioration in symptoms/functional
status. If an observed patient fails to improve spontane-
ously within 3e6 months, treatment could be considered
or, conversely, the patient could continue to be observed
off therapy. Third, if a patient is determined to have
residual scarring from sarcoidosis and no active granulo-
matous inflammation, therapy should be withheld even if
the patient has significant pulmonary symptoms, functional
limitation, or pulmonary dysfunction.
In most cases, the presence of pulmonary symptoms is
a necessary but insufficient requirement for the treatment
of pulmonary sarcoidosis because pulmonary symptoms may
be caused by an alternative process. Table 1 lists the
differential diagnosis for pulmonary symptoms in a patient
with pulmonary sarcoidosis. Sarcoidosis associated pulmo-
nary hypertension warrants particular attention because
although it may be considered a form of pulmonary
sarcoidosis, it usually fails to respond to anti-granulomatous
therapy 4 but rather pulmonary vasodilators.5,6 These
alternative causes of pulmonary symptoms need to be
excluded before pulmonary sarcoidosis is treated. Ideally,
the decision to treat a pulmonary sarcoidiosis patient should
be based on some evidence of granulomatous inflammation
plus a pulmonary physiologic abnormality plus evidence of
significant symptoms/functional limitation (Fig. 2).
Probably the pulmonary function test with the greatest
impact concerning decisions for pulmonary sarcoidosis is
the forced vital capacity (FVC). However, asymptomatic
patients with a reduced FVC should not be treated unless
the reduction is major (we suggest <70% of predicted) and
the patient demonstrates evidence of granulomatous
inflammation in the lung (vide infra). Spirometry should
always be obtained as a baseline for future treatment
Table 2 Clinical assessment of granulomatous inflamma-
tion in pulmonary sarcoidosis.
Test Drawbacks
Chest radiograph Test of choice but may
be insensitive
Chest computed
tomography
Radiation exposure, especially
if performed serially
Gallium-67
scan/other nuclear
medicine scans
Radiation exposure
Requires two visits spaced
48 h apart
Positron emission
tomography scan
May be insensitive in detecting
parenchymal granulomatous
inflammation
Bronchoalveolar
lavage cellular
analysis
Relatively invasive, problematic
to perform serially
Serum angiotensin
converting
enzyme level
Not specific for granulomatous
inflammation in the lung
Table 1 The differential diagnosis for pulmonary symp-
toms in a patient with pulmonary sarcoidosis.
Common
Pulmonary sarcoidosis
Bronchitis
Obesity
Inactive fibrosis from sarcoidosisa
Less common
Airway reactivity
Pneumonia
Bronchiectasisa
Steroid myopathy
Psychogenic
Pulmonary hypertension
Ischemic heart disease
Cardiac sarcoidosis
a Usually associated with fibrocystic pulmonary sarcoidosis.
The treatment of pulmonary sarcoidosis 1353decisions. Diffusing capacity is less useful than FVC as an
indication for treatment because of the high variability of
this measurement.7 However, a diffusing capacity should be
obtained because a value significantly lower in percent
predicted than FVC would suggest possible sarcoidosis
associated pulmonary hypertension.8
The treatment of pulmonary sarcoidosis should not be
based entirely on chest radiographic findings. However, as
mentioned (Fig. 2), ideally, evidence of granulomatous
inflammation should be demonstrated along with physio-
logic dysfunction and significant pulmonary symptoms
limitation in order to initiate therapy. Table 2 lists several
clinical tests available to assess the granulomatous
inflammation of sarcoidosis. Of these, chest imaging is the
most reliable. In the proper clinical context, parenchymal
lung nodules 1e5 mm in diameter and infiltrates composed
of conglomerations of these nodules represent granuloma-
tous inflammation in the lung.9e14 These nodules usually
have a perilymphatic distribution.9,10,13 Mediastinal aden-
opathy alone is inadequate evidence of active intra-
parenchymal pulmonary sarcoidosis. Although the structure
of the lung parenchyma is more clearly assessed by chest
CT scanning than by chest radiograph, chest CT scans have
not been recommended as part of the baseline assessment
of pulmonary sarcoidosis.15 In addition, chest CT scansGranulomatous
Activity
measurements
Development of 
granulomas, 
mediators
Dera
pulm
phys
Radiographic imaging
Nuclear imaging
BAL cell counts
Serum ACE
FVC
FEV1
DLCO
6MW
Figure 2 Factors involved in the decision to treat pulmonary sa
granulomatous inflammation, significant physiologic impact resu
functional impact from the physiologic impairment. Measurements
BAL, bronchoalveolar lavage; ACE, angiotensin converting enzyme;
1 s; DLCO, diffusing capacity; 6MWT, 6-minute walk test (distance)expose patients to significant radiation, especially if they
are performed serially.16 Therefore, we do not recommend
routine initial chest CT scans as an integral part of the
assessment of pulmonary sarcoidosis nor the need for
therapy. Chest CT scans may be useful to detect active
parenchymal disease in a patient with a normal chest
radiograph. The presence of fibrocystic disease on chest
imaging may suggest that the patient has a propensity for
further lung fibrosis, which might lower the threshold for
administering anti-sarcoidosis treatment; however, based
on presently available data, the identification of lung
fibrosis in and of itself does not mandate therapy. It is the
author’s opinion that there three main indications to
perform a chest CT scan in sarcoidosis:
 The presence of significant pulmonary symptoms and/
or pulmonary dysfunction when a chest radiograph
shows no parenchymal disease (scadding stage 0, 1).
 Evaluation of pulmonary fibrosis when it is not evident
on a chest radiograph.
 Hemoptysis (bronchiectasis, broncholithiasis,mycetoma).
Although the role of chest imaging in pulmonary
sarcoidosis treatment decisions is complementary to thePhysiologic 
Impact
Functional
Impact
ngement of 
onary 
iology
Functional 
impairment, 
symptoms
T
Pulmonary Symptoms
HRQoL
rcoidosis. Ideally, treatment should be based on evidence of
lting from the granulomatous inflammation, and significant
in bold represent the most common measurements assessed.
FVC, forced vital capacity; FEV1, forced expiratory volume in
; HRQoL, health related quality of life questionnaires.
1354 M.A. Judsonpresence of significant pulmonary symptoms/functional
limitation, it is essential that a chest imaging be obtained
initially because alternative causes for these symptoms
may be identified (e.g. pneumonia, congestive heart
failure).
Additional indicators of granulomatous inflammation
other than the chest imaging (Table 2) are not generally
useful to make treatment decisions. These tests may be
useful in making treatment decisions if radiographic chest
imaging studies fail to demonstrate active granulomatous
lung disease.
Practically speaking, not all patients will pulmonary
sarcoidosis will demonstrate significant pulmonary symp-
toms, pulmonary dysfunction, and evidence of granuloma-
tous inflammation (Fig. 2). At times, treatment decisions
will need to be based on the presence of some, but not all
of these factors. This is taken into account in Fig. 3 which
outlines an approach to the initial decision to treat
pulmonary sarcoidosis.Pulmonary S
none or minimal mild to mo
DO NOT TREAT unless 
FVC <70% predicted* AND
there is evidence of active 
granulomatous inflammation 
(table 2)
May consider inhaled 
corticosteroids (Table 4) for 
cough.
Identify alternati
of pulmonary sy
(table 1)
No alternative 
cause found
Detect evidence of 
granulomatous infla
(table 2) and/or FVC
the lower limits of n
Do not treat. 
Reconsider 
alternative cause 
of symptoms. 
May consider 
treatment if 
symptoms 
persist.
Consider t
(figure 6, t
symptoms
of life decr
significant
OR
Consider 
observatio
months: 
If deteriora
(figure 6, t
If improve
resolution,
treat.
If stable, c
treatment 
table 3) or
to observe
Not 
detected
Figure 3 The treatment approach to newly diagnosed disease.
substitute FVC criteria with another objective measure of physiolo
diffusing capacity).Therapy for established disease
There is ample evidence to suggest that sarcoidosis, like most
other granulomatous diseases, occurs when an antigen comes
in contact with the host’s immune system leading to
a sequence of events resulting in the sarcoid granuloma. This
process involves the interplay of inflammatory cells, cell
receptors, cytokines, andHLAmolecules. It is thought that the
granulomatous response in sarcoidosis represents an attempt
by the host to clear the putative antigen. If the antigen can be
cleared, the granulomatous reaction will cease.
This concept has implications concerning the issue of
relapse. Therapy in sarcoidosis may be a double-edged
sword in that while it may eliminate the granulomatous
inflammation, it may interfere with the very process of
antigen clearance. Therefore, therapy may prevent the
antigen from being cleared which would result in the
granulomatous process resuming once anti-granulomatous
therapy is withdrawn (relapse). Indeed, there is evidenceymptoms
derate severe
ve cause 
mptoms 
Identify alternative cause 
of pulmonary symptoms
(table 1)
Alternative cause 
found
Treat alternative cause
No alternative 
cause found
active 
mmation 
 below 
ormal*
Detect evidence of active 
granulomatous inflammation 
(table 2) and/or FVC below 
the lower limits of normal*
reatment 
able 3) if 
 or quality 
ement is 
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n for 3-6 
tion, treat. 
able 3)
ment or 
 do not 
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 continue 
.
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of symptoms. 
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Treat 
(figure 6, 
table 3)
detected
Not 
detected
detected
FVC: forced vital capacity. )Suggested by the author. Could
gic impairment (e.g., forced expiratory volume in one second,
  
 
 
Significant change in pulmonary symptoms
The treatment of pulmonary sarcoidosis 1355to support this premise. Studies have shown that sarcoidosis
patients receiving corticosteroid therapy have a higher rate
of relapse than those who are observed without anti-
sarcoidosis therapy.17 In addition, in a study of sarcoidosis
patientswhowereall treatedwith corticosteroids, thosewho
relapsed received a higher mean dose (17.0 vs 10.6 mg of
prednisolone, p< 0.05, NZ 82).18 Furthermore, it has never
been clearly demonstrated that the treatment of sarcoidosis
affects the natural course of the disease.19,20 To that end,
adequate therapy for sarcoidosismaybemore amatter of the
duration of therapy than the use of specific medications or
specific doses. As long as the duration of an anti-sarcoidosis
regimen exceeds the presence of the antigen in the host,
the therapy will be “effective.” On the other hand, if the
regimen is discontinued while the antigen is still present, the
patient will “relapse” (Fig. 4). This schema also suggests that
the initial treatment of pulmonary sarcoidosis and the
treatment of a relapse may represent an identical immuno-
pathological process and may respond to identical therapy.
Therefore, the decision to restart therapy or increase
the intensity of therapy for relapse of pulmonary sarcoi-
diosis is based on the same principles involved in the
decision to initiate treatment. A clear indication for
treatment would be if the patient develops evidence of
increased pulmonary granulomatous inflammation (e.g. on
chest imaging), evidence of worsening pulmonary dysfunc-
tion (e.g. a reduction in FVC), and worsening pulmonary
symptoms (Fig. 2). Similar to the decision to treat initial
presentations of pulmonary sarcoidosis, many times treat-
ment decisions must be based on the presence of some, but
not all of these three factors. If a patient has significant
worsening of pulmonary symptoms, we propose (arbitrarily
without supporting clinical data) that a relative reduction
in FVC of >5% is ample evidence to consider treatment. If
the patient is without symptoms, the odds of a change in
FVC being as a result of worsening pulmonary sarcoidosis
are probably less than from random variation or error of the
measurement. In these cases, therapy should usually beresolution
Time
Therapy A
no relapse
relapse
Therapy B
natural course of sarcoidosis
Figure 4 The duration of therapy could determine the chance
of relapse because sarcoidosis treatment may not affect the
natural course of disease. If the duration of therapy exceeds the
duration of disease activity (Therapy A), then the patientwill not
relapse when therapy is withdrawn. If the duration of therapy is
shorter than the duration of disease activity (Therapy B), then
the patient will relapse when therapy is withdrawn.withheld. If therapy in considered in this situation, the
threshold for a significant change in FVC should be set high,
such as reduction of >10% of predicted (an arbitrary recom-
mendation that is not supported by clinical data). Therapy
could be considered in an asymptomatic pulmonary sarcoid-
osis patient with such a reduction in FVC provided that the
patient has evidence of active granulomatous inflammation
(Table 2) or was thought to be unreliable in reporting his
pulmonary symptoms. As with the decision to initiate treat-
ment of pulmonary sarcoidosis, isolated changes in chest
imaging or other markers of granulomatous inflammation
should not prompt treatment. Nonetheless, chest imaging
should be obtained to exclude alternative pulmonary condi-
tions and a diffusing capacity should be considered if the
development of sarcoidosis associated pulmonary hyperten-
sion is a possibility. Pulmonary symptoms should not be
treated without some evidence of active granulomatous
inflammation or pulmonary dysfunction. In these circum-
stances, alternative causes for thedevelopmentorworsening
of pulmonary symptoms should be excluded (Table 1); this
evaluation should include a measurement of diffusing
capacity to evaluate the possibility of pulmonary hyperten-
sion. Fig. 5 outlines the treatment approach for patients with
established pulmonary sarcoidosis.
Specific pharmacotherapy
Recommended corticosteroid treatment course
When the decision is made to treat pulmonary sarcoidosis,
corticosteroidsareusuallyused. InaDelphi studyof sarcoidosis
experts, 33/36 (92%) recommended corticosteroids alone asNO YES
DO NOT TREAT unless FVC decline 
of >10% predicted* AND there is 
evidence of active granulomatous 
inflammation (table 2)
Identify alternative cause of 
pulmonary symptoms (table 1)
Alternative 
cause found
No alternative 
cause found
Detect evidence of 
active granulomatous 
inflammation (table 2) 
and/or relative FVC 
decline of >5% * 
Treat 
alternative 
cause
Do not treat. 
reconsider 
alternative cause 
of symptoms. 
May consider 
treatment if 
symptoms 
persist.
If not previously 
treated, treat with 
initial treatment. 
(figure 6, table 3) 
If previously 
treated, treat for 
relapse. (figure 7)
detected
Not 
detected
Figure 5 The treatment approach for established disease.
FVC, forced vital capacity. )Suggested by the author. Could
substitute FVC criteria with another objective measure of
physiologic impairment (e.g., forced expiratory volume in one
second, diffusing capacity).
Figure 6 Corticosteroid (6 phase) treatment for pulmonary
sarcoidosis. See Table 3 for suggested doses and duration of
therapy in each phase. Ref. 1, reproduced with permission.
corticosteroid taper
No 
relapse
Relapse, 
No fibrosis, 
no significant 
corticosteroid 
toxicity
Relapse, 
No fibrosis,
significant 
corticosteroid 
toxicity
Relapse, 
fibrosis 
present,
corticosteroid treatment 
(figure 6, table 3).
Consider adding 
corticosteroid sparing 
agent if cumulative 
corticosteroid therapy >1 
year.
Add corticosteroid 
sparing agent and then 
start corticosteroid 
treatment
(figure 6, table 3) 
Taper corticosteroid dose to <10mg/day of prednisone 
No relapse
Observe without 
therapy
No relapse
Observe without 
therapy
relapse relapse
successful unsuccessful
Maintain on lowest 
effective corticosteroid 
dose. 
Consider adding 
corticosteroid sparing 
agent if corticosteroid 
toxicity develops or risk 
of corticosteroid toxicity 
is high. 
Can consider tapering 
off corticosteroids.
Add corticosteroid 
sparing agents to reduce 
corticosteroid dose to 
<10mg/day of 
prednisone.
Maintain on lowest 
effective corticosteroid 
dose. 
Can consider tapering 
off corticosteroids.
Figure 7 The treatment approach to relapse during or after
a corticosteroid taper.
1356 M.A. Judsonthe initial therapy.21 Corticosteroids are almost uniformly
beneficial in improving symptoms and pulmonary function in
acute pulmonary sarcoidosis.
The initial corticosteroid dose is not standardized and
sarcoidosis experts were unable to reach a consensus in
a Delphi study.21 The official sarcoidosis consensus state-
ment of the American Thoracic Society/European Respira-
tory Society/World Association of Sarcoidosis and Other
Granulomatous Diseases (WASOG) recommends a daily
prednisone equivalent of 20e40 mg for the initial treat-
ment of pulmonary sarcoidosis.15 It is recommended that
this dose be continued for 1e3 months and then tapered to
a 5e10 mg/day maintenance dose and that this treatment
be continued for one year before corticosteroid therapy is
discontinued. This approach has been described as “the six
phases of treatment for pulmonary sarcoidosis:” initial
dosing, taper to maintenance, maintenance dosing, taper
off, observation, treatment of relapse (if required) (Fig. 6,
Table 3).1 The duration of corticosteroid treatment is based
on the premise that it is unlikely that the sarcoidosis
antigen will cleared in less than 1 year and, therefore,
relapse is highly likely with shorter regimens. Some have
suggested modifications to the dosing schedule of the six
phases of treatment including that the duration of corti-
costeroid therapy can be shortened to 6 months22 and that
the maintenance phase corticosteroid dose may be given
every other day to minimize corticosteroid side effects.23
Recently a shorter, low intial dose (“phase 1”) has been
proposed for pulmonary sarcoidosis consisting of 20 mg of
daily prednisone for amedian of 3 weeks.24 This regimenwas
effective in returning pulmonary function to baseline and
relieving pulmonary symptoms. This regimen was given for
acute pulmonary exacerbations of sarcoidosis and not initialTable 3 Recommendation for the (6 phase) treatment of pulm
Phase Daily doseb
1. Initial dosing 20e40
2. Taper to maintenance N/A
3. Maintenance dosing 5e15
4. Taper off corticosteroid therapy N/A
5. Monitor while not receiving therapy N/A
6. Treatment of relapse See Fig. 7
N/A, not applicable.
a Adapted from Ref. 1.
b Prednisone equivalent in mg.therapy. However, as discussed above, there is evidence that
initial treatment and treatment of exacerbations of pulmo-
nary sarcoidosiswill respond identically. Aneven lower initial
dose of 15 mg of prednisone has been shown to be effective
initial therapy for pulmonary sarcoidosis.25
Therapy for relapse
Relapses occur in 20 to more than 70 percent of patients in
whom corticosteroids are discontinued.17,26 Corticosteroid
therapy for the treatment of relapses may be used identi-
cally as for the initial treatment of pulmonary sarcoidosis.
Pulmonary sarcoidosis is relatively sensitive to corticoste-
roids compared to other forms of sarcoidosis, with an
almost universal response to 20 mg of daily prednisone
equivalent.24 Because most of the side effects from corti-
costeroids are cumulative (e.g., weight gain, osteoporosis,
cataracts), the additional corticosteroid treatment ofonary sarcoidosis.a
Time period Reference
2e6 Weeks 22, 24, 26, 38
6 Weekse6 months 22, 26, 38
5e9 Months 22, 38
1e6 Months 22, 38
N/A
See Fig. 7 See Fig. 7
Table 4 Alternative/corticosteroid sparing drug for the treatment of pulmonary sarcoidosis.
Drug Level of
evidencea
Standard dose Side effectsb Monitoring Comments Reference
Methotrexate 1A 5e20 mg/week Nausea, fatigue, stomatitis,
alopecia, hepatits, bone
marrow suppression,
pneumonitis
CBC, LFT Folic acid, 1 mg/day may
reduce toxicity
27,41,42
Leflunomide 1B 10e20 mg/day Diarrhea, nausea,
hepatitis, alopecia,
neuropathy
CBC, LFT Because the drug has a long
half life, cholestyramine may
be needed to excrete the
drug if toxicity develops
43,44
Azathioprine 1B 50e200 mg/day Nausea, myalgia,
diarrhea, hepatitis,
bone marrow suppression
CBC, LFT Consider measurement of
thiopurine methyltrasferase
level prior to drug initiation
as low levels suggest that the
drug will accumulate and
increase the risk of toxicity
45,46
Mycophenolate 1C 500e3000 mg/day Nausea, diarrhea,
hepatitis, bone marrow
suppression
CBC, LFT Should be avoided in women
of child bearing potential as
it is associated with
miscarriage and congenital
malformations
47,48
Infliximab 1Ac 3e5 mg/kg
intravenously,
then 2 weeks
later, then every
4e8 weeks
Allergic reactions,
tuberculosis, lymphoma,
/malignancy, central
demyelinating disease
Ascertain symptoms of
tuberculosis or potential
contacts with individuals
with active tuberculosis
All patients require a negative
tuberculin skin test or negative
whole blood interferon release assay
versus tuberculosis proteins
before initiation of therapy.
32,49
Adalimumab 1Cc 40 mg
subcutaneously
every 1e2 weeks
Allergic reactions,
tuberculosis, lymphoma,
/malignancy, central
demyelinating disease
Ascertain symptoms of
tuberculosis or potential
contacts with individuals
with active tuberculosis
All patients require a negative
tuberculin skin test or negative
whole blood interferon release
assay versus tuberculosis
proteins before initiation of
therapy.
50
Pentoxifylline 2C 400e1200 mg/day Nausea, diarrhea,
abdominal bloating,
constipation, dizziness
CBC, LFT Not an extremely potent
agent for pulmonary sarcoidosis
51,52
Chloroquine 2B 250e750 mg/day Retinal damage Ophthalmology
examinations
Hydroxychloroquine is less
likely to cause retinal toxicity
but is probably less potent for
pulmonary sarcoidosis
53,54
(continued on next page)
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1358 M.A. Judsonrelapses significantly increases the risk of such toxicities.
For this reason, alternative agents to corticosteroids are
recommended for patients who are corticosteroid-
dependent or have frequent relapses. These agents
should be considered in such patients and those who are
corticosteroid-dependent for a cumulative period of more
than 1 year. Fig. 7 outlines the approach to relapse, which
includes indications to use alternative agents to cortico-
steroids. The decision to use these agents is affected by the
duration of previous corticosteroid therapy, the mainte-
nance corticosteroid dose to control the disease, and the
propensity for fibrosis.
Table 4 lists corticosteroid-sparing alternative agents
useful for the treatment of pulmonary sarcoidosis. Alterna-
tive agents to corticosteroids are rarely effective alone for
the treatment of sarcoidosis but often allow for a reduction
in the maintenance corticosteroid dose (corticosteroid
sparing). Most alternative agents require 3e9 months to
reach peak efficacy for the treatment of pulmonary
sarcoidosis. Therefore, corticosteroids should be slowly
taperedafter analternativeagent is added.Thesedata imply
that it is unrealistic to expect an immediate switch from
corticosteroids to an alternative agent will be effective for
the treatment of pulmonary sarcoidosis; and complete
withdrawal of corticosteroids is likely to result in relapse.27
Some have recommended that an alternative agent be
added to corticosteroids for the initial treatment of pulmo-
nary sarcoidosis,28 However, this approach is not recom-
mended since a large percentage of treated patients will not
relapse and, therefore, will avoid the potential toxicity of
a second agent if they are treated with corticosteroid alone.
Methotrexate is the most well studied of all the alterna-
tive agents for the treatment of pulmonary sarcoidosis. It is
also the only non-corticosteroid therapy which has demon-
strated equivalence to corticosteroids as a single agent for
acute disease.29 A consensus of sarcoidosis experts (25/30,
83%) selected methotrexate as the preferred second line
agent for pulmonary sarcoidiosis.21 Infliximab is usually
reserved as a third line therapy behind the other agents
because of cost and the difficulties of intravenous adminis-
tration. Other tumor necrosis factor antagonists such as
adalimumab and golimumab may have a limited role in the
treatment of pulmonary sarcoidosis. Inhaled corticosteroids
may be useful for the treatment of sarcoidosis related cough,
although high doses are often required.
Fig. 7 outlines an algorithm for the treatment of relapses
of pulmonary sarcoidosis. The decision to give these agents
is affected by the duration of previous corticosteroid
therapy, the maintenance corticosteroid dose required to
control the disease, and the propensity for fibrosis.Therapy for pulmonary fibrosis from sarcoidosis
The phenotypic characterization of pulmonary sarcoidosis
is not standardized. Descriptions such as “acute,”
“subacute,” “chronic” and “persistent” have been
described.30e32 Some of these classifications have been
associated with the production of inflammatory media-
tors.30 Nonetheless, presently, there is insufficient data to
base treatment decisions on specific phenotypes. Some
have defined “chronic disease” as disease that is active
The treatment of pulmonary sarcoidosis 1359over a specific period of time such as 1 year,32 2 years33 or 5
years.2 We believe that treatment decisions of patient with
chronic pulmonary sarcoidosis should be based on the
propensity to develop pulmonary fibrosis rather than the
duration of disease. It is this subgroup of patients that
develop major life-threatening complications of the disease
such as respiratory failure,34 pulmonary hypertension,35
and mycetoma.36
Despite the lack of specific recommendations, certain
principles should be kept in mind when treating fibrotic
disease.First, threequartersofpulmonarysarcoidosis patients
who requiremore than 5 years of corticosteroid treatmentwill
experience a relapsewhen therapy is withdrawn.37 Therefore,
although an attempt can be made to taper such a patient off
therapy, a few failures of this approach may prompt a consid-
eration of identifying the lowest dose and least toxic chronic
regimen rather than continuing with the “6 phases” approach
where the patient continues to receive relatively high dose
“corticosteroid bursts” with each relapse. Second, when
considering adding alternative corticosteroid sparing agents,
these regimens should be compared to chronic low dose
corticosteroid therapy alone.Over 90%of patientswho require
long-term corticosteroids can be maintained on 15 mg of
daily prednisone and 65% on10 mg of daily prednisone.1,37 In
general, complications fromcorticosteroids at10 mg of daily
prednisone are not permanent or serious (weight gain is most
common).37,38 These data suggest that a chronic maintenance
dose of 10 mg of daily prednisone equivalent may be less
toxic than adding a corticosteroid sparing drug with its own
additional toxicities. In support of this contention, a Delphi
study of sarcoidosis experts reached a consensus that a corti-
costeroid taper to a maintenance dose of 10mg of daily
prednisone equivalent for pulmonary sarcoidosis is considered
“a successful taper.”21 Third, pulmonary sarcoidosis patients
with a chronic course who develop fibrotic disease are at high
risk of progressive disease causing further lung damage.39,40 In
general, such patients should be treated more aggressively
than those who have chronic disease manifesting as multiple
non-fibrotic granulomatous relapses (Fig. 7).Summary
Pulmonary sarcoidosis does not mandate therapy. Therapy
should be given to patients who have (a) evidence of
granulomatous inflammation; (b) evidence of pulmonary
dysfunction; plus (c) pulmonary symptoms that are signifi-
cantly affecting the patient’s quality of life or functional
status. If one of these three components is absent, the
clinician should be cautious in assuming that the patient
has active disease that warrants therapy. Of these three
components, symptoms carry the most weight. Patients
without symptoms or functional limitation should usually
not be treated even if there is evidence of granulomatous
inflammation and/or worsening pulmonary physiology, as
the avoidance of the toxicities of therapy may outweigh the
benefits of treatment.
Pulmonary sarcoidosis is usually rapidly responsive to
relative low doses of prednisone. However, the relapse rate
is high. Therefore, prolonged, low dose corticosteroid
courses are often required for initial treatment. When
patients develop relapses or become corticosteroiddependent, they should be considered for alternative
corticosteroid sparring therapy. Such therapy is especially
reasonable in patients who require high maintenance doses
of corticosteroids or require corticosteroids for an
extended period of time.Conflict of interest
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